Drug

HutchMed's Orpathys Plus Tagrisso Combination Wins Regulatory Review Acceptance in Europe and Japan for Post‑Tagrisso NSCLC
CancerCombination therapy

HutchMed’s Orpathys Plus Tagrisso Combination Wins Regulatory Review Acceptance in Europe and Japan for Post‑Tagrisso NSCLC

HutchMed (China) Limited (NASDAQ: HCM; HKG: 0013) announced that regulatory applications for the combination therapy of Orpathys (savolitinib) and Tagrisso (osimertinib) have been accepted for review in Europe and Japan.…

InventisBio's Oral TYK2 Inhibitor Nomelcitinib Meets Primary Endpoint in Phase III Trial for Moderate-to-Severe Plaque Psoriasis – PASI 90 Above 70% at Week 16

InventisBio’s Oral TYK2 Inhibitor Nomelcitinib Meets Primary Endpoint in Phase III Trial for Moderate-to-Severe Plaque Psoriasis – PASI 90 Above 70% at Week 16

Nuance Pharma Doses First Participant in REACH Phase III Trial of STG320 for House Dust Mite Allergic Rhinitis in China

Nuance Pharma Doses First Participant in REACH Phase III Trial of STG320 for House Dust Mite Allergic Rhinitis in China

Empowering Chinese Pharma’s Global Expansion

Leverage premier media reach to connect your pipeline with global partners. Contact us to drive your international growth today.
Contact US
Eli Lilly’s Lebrikizumab Demonstrates Four-Year Sustained Efficacy in Atopic Dermatitis, Reinforcing IL-13 as Core Therapeutic Target
Auto-immuneClinical trial results

Eli Lilly’s Lebrikizumab Demonstrates Four-Year Sustained Efficacy in Atopic Dermatitis, Reinforcing IL-13 as Core Therapeutic Target

UCB's Bimzelx Wins NMPA Approval for Two New Indications – IL-17A/F Dual-Target Antibody Expands into Psoriasis and Hidradenitis Suppurativa
Auto-immuneEBR: UCB

UCB’s Bimzelx Wins NMPA Approval for Two New Indications – IL-17A/F Dual-Target Antibody Expands into Psoriasis and Hidradenitis Suppurativa

Enhertu Wins China Approval for HER2+ Early Breast Cancer – ADC Sequential Therapy Shows 67% pCR Rate in Phase III DESTINY-Breast11
ADC / XDCAstraZeneca

Enhertu Wins China Approval for HER2+ Early Breast Cancer – ADC Sequential Therapy Shows 67% pCR Rate in Phase III DESTINY-Breast11

Gene therapyRare / orphan disease drugs

FDA Approves Rocket Pharma’s Kresladi – First Gene Therapy for Severe Leukocyte Adhesion Deficiency Type I

Show More